Shanghai RAAS Blood Products (002252.SZ): Application for Additional Clinical Trial Indication for "SR604 Injection" Accepted

Shanghai RAAS Blood Products (002252.SZ) announced that the Company recently received the "Notice of Acceptance" issued by the National Medical Products Administration (NMPA) regarding the Investigational New Drug (IND) application for SR604 Injection. The IND application acceptance number is CXSL2601243. In accordance with Article 32 of the Administrative Licensing Law of the People's Republic of China, upon review, the application has been decided to be accepted. During the same period, the Center for Drug Evaluation (CDE) of the National Medical Products Administration published a notice stating that, in accordance with the Guidelines for Application to the Rare Disease Innovative Drug Development Encouragement Pilot Program ("Care Plan-Extension"), SR604 Injection (proposed indications: "Glanzmann thrombasthenia" and "preventive treatment of von Willebrand disease") is proposed to be included in the "Care Plan-Extension" pilot program. The public notice period runs until November 10, 2026.